



THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A compound of the formula (I)



wherein:

- 5 R<sub>2</sub> is selected from hydrogen, hydroxyl, O-alkyl, O-alkenyl, O-benzoyl, O-alkanoyl, O-alkenoyl, O-aryl, O-heterocyclic, O-heteroaryl or




- 10 wherein R<sub>5</sub> and R<sub>7</sub> are independently be selected from hydrogen, alkanoyl, alkenoyl, benzoyl or benzoyl alkyl substituted alkanoyl;

R<sub>3</sub> is selected from hydroxyl, O-alkanoyl, O-alkenoyl, O-benzoyl, O-alkyl, O-alkenyl, O-aryl, O-heterocyclic or O-heteroaryl;


R<sub>4</sub> is selected from -CH<sub>2</sub>OH, COOH, CH<sub>2</sub>OCOCH<sub>3</sub>, COO alkyl, COO aryl, CH<sub>2</sub>COO alkyl, COO-heterocyclic, COO-heteroaryl, CH<sub>2</sub>-O aryl, CH<sub>2</sub>O heterocyclic or CH<sub>2</sub>O heteroaryl;

15 R<sub>6</sub> is selected from hydrogen or



R<sub>1</sub> is selected from hydrogen or alkyl; or  
pharmaceutically acceptable salts thereof, with the provisos that when:  
R<sub>2</sub> is OH, R<sub>3</sub> is OH, R<sub>4</sub> is CH<sub>2</sub>OH, and R<sub>6</sub> is xylopyranosyl, R<sub>1</sub> is not H;  
5 R<sub>4</sub> is CH<sub>2</sub>OH and R<sub>3</sub> is O-alkanoyl R<sub>2</sub> is not O-acetyl; .  
R<sub>4</sub> is CH<sub>2</sub>OH and R<sub>2</sub> is O-alkenoyl R<sub>3</sub> is not hydroxyl; and  
R<sub>4</sub> is CH<sub>2</sub>OH and R<sub>3</sub> is hydroxyl then R<sub>2</sub> is not hydroxyl..

2. A compound as claimed in claim 1 wherein R<sub>2</sub> is hydrogen, O-benzoyl, O-tigloyl or



10

wherein R<sub>5</sub> and R<sub>7</sub> are selected from hydrogen, tigloyl, benzoyl or benzoyl alkyl substituted alkanoyl.

3. A compound as claimed in claim 1 wherein R<sub>3</sub> is selected from O-acetyl, O-benzoyl, O-isobutyryl or O-tigloyl.

15 4. A compound as claimed in claim 1 wherein R<sub>4</sub> is selected from -CH<sub>2</sub>OH, O-acetyl or hydroxyl.

5. A compound as claimed in claim 1 wherein R<sub>2</sub> is arabino pyranosyl, 3-(3-benzoyl-2-methylbutanoyl)-4-benzoyl- $\alpha$ -L-arabinopyranosyl, O-benzoyl, O-dibenzoyl, O-tigloyl, 3,4 dibenzoyl  $\alpha$ -L-arabinopyranosyl, 3-(3-benzoyl-2 methylbutyryl-4-tigloyl- $\alpha$ -L-arabinopyranosyl, 3-tigloyl-4-(3-benzoyl-2 methylbutyryl)- $\alpha$ -L-arabinopyranosyl, 3-(3-benzoyl-2 methyl butanoyl-4-benzoyl- $\alpha$ -L-arabinopyranosyl or 3-(3-benzoyl-2 methylbutyryl)-4-benzoyl- $\alpha$ -L-arabinopyranosyl.

20 6. A compound as claimed in claim 1 wherein R<sub>6</sub> is methyl.

25 7. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21-O-[3-(3-benzoyl-2-methylbutanoyl)-4-benzoyl- $\alpha$ -L-

- arabinopyranosyl]-22-O-acetyl barringtogenol C;
8. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21-O-benzoyl barringtogenol C;
9. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21-O-benzoyl-28-O-acetyl barringtogenol C;
10. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21-O-benzoyl-22-O-isobutyryl barringtogenol C;
11. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-methylglucuronopyranosyl-21,22-O-dibenzoyl barringtogenol C;
12. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21, 22-O-dibenzoyl barringtogenol C;
13. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-methylglucuronopyranosyl-21-O-benzoyl-22-O-tigloyl barringtogenol C;
14. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21-O-benzoyl-22-O-tigloyl barringtogenol C;
15. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-methylglucuronopyranosyl-21,22-O-tigloyl barringtogenol C;
16. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]-D-glucuronopyranosyl-21,22-O-tigloyl barringtogenol C;
17. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-22-O-benzoyl barringtogenol C;
18. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21-O-[3,4-dibenzoyl- $\alpha$ -L-arabinopyranosyl]-22-O-acetyl barringtogenol C;
19. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21-O-[3,4-dibenzoyl- $\alpha$ -L-arabinopyranosyl]-28-O-acetyl barringtogenol C;
20. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21-O-[3-(3-benzoyl-2-methylbutyryl)-4-tigloyl- $\alpha$ -L-arabinopyranosyl]-22-O-acetyl barringtogenol C;
21. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21-O-[3-tigloyl-4-(3-benzoyl-2-methylbutyryl)- $\alpha$ -L-

arabinopyranosyl]-22-O-acetyl barringtogenol C;

22. 3-O- $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)- $\beta$ -D-glucuronopyranosyl-21-O-[3-(3-benzoyl-2-methylbutyryl)-4-benzoyl- $\alpha$ -L-arabinopyranosyl]-22-O-acetyl barringtogenol C.

5 23. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21-O-[3-(3-benzoyl-2-methylbutyryl)-4-benzoyl- $\alpha$ -L-arabinopyranosyl]-28-O-acetyl barringtogenol C.

24. A pharmaceutical composition for treatment and/or control of pain comprising a therapeutically effective amount of a compound of any one  
10 of claims 1 to 23 and a pharmaceutically acceptable carrier.

25. A pharmaceutical composition as claimed in claim 24 wherein the carrier is a pharmaceutically acceptable excipient.

26. A method of treating and/or controlling pain which includes the step of administering to a subject in need of such treatment at least one  
15 compound as claimed in any one of claims 1 to 23.